CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 106 enrolled
Drug / intervention
IMC-1121B (ramucirumab) +1 morebiological
Likely dose
IMC-1121B (ramucirumab) 10 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00533702
NCT00533702Phase 2Completed
CompareCT.gov

Phase II Randomized, Open-Label Study of IMC-1121B With or Without Dacarbazine in Patients With Metastatic Malignant Melanoma

Eli Lilly and Company·interventional·Posted Sep 21, 2007·Updated Aug 1, 2014

In Brief

A Phase 2 clinical trial evaluating IMC-1121B (ramucirumab) and Dacarbazine for Metastatic Malignant Melanoma. Completed, enrolled 106 participants across 17 sites.

Detailed Summary

The primary objective of this study is to determine the progression-free survival (PFS) of participants with previously untreated metastatic malignant melanoma when treated with IMC-1121B (ramucirumab) alone or in combination with dacarbazine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Malignant Melanoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 21, 2007
Enrollment StartNov 1, 2007
Primary CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 18.8 years ago

Interventions

IMC-1121B (ramucirumab)biological

10 milligrams/kilogram (mg/kg) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.

Dacarbazinedrug

1000 milligrams/square meter (mg/m2) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.